| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 09/02/2004 | US20040170684 For therapy of incontinence |
| 09/02/2004 | US20040170683 Tablets comprising modafinil |
| 09/02/2004 | US20040170682 Process for activation of drugs in a vibrational mill |
| 09/02/2004 | US20040170681 Fast acting paracetamol formulation containing a small amount of antacid |
| 09/02/2004 | US20040170680 For orally administering oxycodone to provide analgesic therapy beyond its relatively short half-life over an extended period of time, and having a duration of pain relief of at least 24-hours |
| 09/02/2004 | US20040170679 Apparatus and methods for forming patterned soft gelatin capsules |
| 09/02/2004 | US20040170678 Liposomal antineoplastic drugs and uses thereof |
| 09/02/2004 | US20040170677 Method of drug loading in liposomes by gradient |
| 09/02/2004 | US20040170676 Mixture for transdermal delivery of low and high molecular weight compounds |
| 09/02/2004 | US20040170675 Topical application of one or more calcium channel blocker agents suspended in one or more carriers with penetration enhancing agent's to effect transdermal delivery of the calcium channel blocker agent |
| 09/02/2004 | US20040170674 Noninvasive methods for treating hemangiomas |
| 09/02/2004 | US20040170673 Adhesive emulsion for medical purposes made from ethylene-vinyl acetate copolymers and adhesive resins |
| 09/02/2004 | US20040170672 For therapy of patients suffering from schizophrenic psychoses |
| 09/02/2004 | US20040170666 Eye coverings |
| 09/02/2004 | US20040170665 Intravitreal botulinum toxin implant |
| 09/02/2004 | US20040170658 capable of absorbing up to at least twice its weight of water, obtained by hemi-synthesis from a mixture of unsaturated fatty acids, esters, unsaturated hydrocarbons or unsaturated derivatives and compounds with hydroxyl functions, preferably without a catalyst and in an atmosphere devoid of oxygen. |
| 09/02/2004 | US20040170654 bolus injection to skin; increased systemic absorption produced compared to absorption produced on delivering the agonist subcutaneously by bolus injection; particularly applicable to tricyclic nitrogen-containing compounds, e.g., R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinoline-2(1H)-thione |
| 09/02/2004 | US20040170650 Pharmaceutical compositions having a modified vehicle |
| 09/02/2004 | US20040170641 Prevention and treatment of amyloidogenic disease |
| 09/02/2004 | US20040170640 Methods for preparing and delivering adjuvant compositions |
| 09/02/2004 | US20040170639 administering by whole body spray a live avirulent derivative of an enteropathogenic bacterium that contains a recombinant gene encoding the protein, other than one that causes respiratory disease in birds; vaccines |
| 09/02/2004 | US20040170632 Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan |
| 09/02/2004 | US20040170623 having a concentration of at least 50 mg/ml of the antibody and containing an acidic component; nasal sprays and slow release formulations drying or freeze-drying |
| 09/02/2004 | US20040170613 Compositions and methods for liver growth and liver protection |
| 09/02/2004 | US20040170588 Polyethersiloxane copolymer in aqueous solution |
| 09/02/2004 | US20040170576 Preparation for saliva flow |
| 09/02/2004 | US20040170575 Aerosol composition comprising silicate particles and polymers |
| 09/02/2004 | US20040170573 Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route |
| 09/02/2004 | US20040170572 Delivery of rizatriptan or zolmitriptan through an inhalation route |
| 09/02/2004 | US20040170571 Delivery of diazepam through an inhalation route |
| 09/02/2004 | US20040170570 Delivery of rizatriptan or zolmitriptan through an inhalation route |
| 09/02/2004 | US20040170569 Dosage forms that rapidly produces peak plasma concentrations; heating a thin layer of the drug on a solid support to form a vapor; and passing air through the heated vapor to produce aerosol particles having less than 10% drug degradation products |
| 09/02/2004 | US20040170568 Stabilized preparations for use in metered dose inhalers |
| 09/02/2004 | US20040170567 Mixture of drug and deactivating compound; separated by (semi)permeable membrane; partitions become impervious upon activation |
| 09/02/2004 | US20040170565 Novel ultrasound contrast agents |
| 09/02/2004 | US20040170560 Liposome confining prodrug, radioactive materials; multilayer; storage stability; antiinflammatory agents; infection therapy; antitumor agents imaging for diagnosis |
| 09/02/2004 | US20040169298 Microcapsule and production method thereof |
| 09/02/2004 | US20040168739 Metering method for particulate material |
| 09/02/2004 | DE19800277B4 Verfahren zur Rückgewinnung von Arzneistoffen aus Zubereitungen, deren Vorprodukten oder Abfällen Process for the recovery of drugs from preparations, their precursors or Waste |
| 09/02/2004 | DE10306344A1 Gasspeicher zur Speicherung einer vorgegebenen Gasmenge und Freigabe des Gases für eine medizinische Applikation Gas storage for storing a predetermined amount of gas and release of gas for medical application |
| 09/02/2004 | DE10306177A1 Seaweed oil, essential oil, terpene, phosphatidylserine, omega-3 fatty acid, lanolin, selin or D-panthenol concentrate containing excess polysorbate useful as an additive for foods, cosmetics, pharmaceuticals |
| 09/02/2004 | DE10305984A1 Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen Salts of organic acids with clopidogrel and to the use thereof for the preparation of formulations phamazeutischer |
| 09/02/2004 | DE10025971B4 Transdermales therapeutisches System in Plasterform mit verminderter Tendenz zur Wirkstoffkristallisation und seine Verwendung Transdermal therapeutic system in Plasterform with reduced tendency to drug crystallization and its use |
| 09/02/2004 | CA2518313A1 Medicament comprising noble metal fineparticles |
| 09/02/2004 | CA2518311A1 Superoxide anion scavenger |
| 09/02/2004 | CA2517005A1 A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
| 09/02/2004 | CA2516798A1 Menthol solutions of drugs |
| 09/02/2004 | CA2516782A1 Use of steroids to treat ocular disorders |
| 09/02/2004 | CA2516736A1 Drug delivery from embolic agents |
| 09/02/2004 | CA2516452A1 Estradiol metabolites for the treatment of pulmonary hypertension |
| 09/02/2004 | CA2516450A1 Method to treat chronic heart failure and/or elevated cholesterol levels |
| 09/02/2004 | CA2516448A1 Method for preparation of an agglomerate using melt agglomeration |
| 09/02/2004 | CA2516339A1 Dispersing agent for sustained-release preparation |
| 09/02/2004 | CA2516285A1 Self-expanding device for the gastrointestinal or urogenital area |
| 09/02/2004 | CA2516175A1 Occlusion resistant hydrocephalic shunt |
| 09/02/2004 | CA2516096A1 Use of a silica or silica derivative as a sorption material |
| 09/02/2004 | CA2515887A1 Semi-solid immediate-release oral formulations comprising an anticancer hydrophobic agent, a polyglycolised glyceride and a hydrophilic carrier |
| 09/02/2004 | CA2514892A1 Compositions comprising a defined polysaccharide component |
| 09/02/2004 | CA2514889A1 Compositions comprising a polysaccharide component and one or more coating layers |
| 09/02/2004 | CA2514875A1 Rapid absorption selective 5-ht agonist formulations |
| 09/02/2004 | CA2514870A1 Compositions comprising a plurality of particles or agglomerates having a defined particle size |
| 09/02/2004 | CA2514804A1 Compositions containing creatine, creatinine and a methyl xanthine |
| 09/02/2004 | CA2514061A1 Combination therapy for the treatment of immunoinflammatory disorders |
| 09/02/2004 | CA2484424A1 Alginate foam compositions |
| 09/01/2004 | EP1452546A2 Poly-beta-1,4-N-Acetyglucosamine |
| 09/01/2004 | EP1452254A1 Preparation of metallic nanoparticle with shell-crosslinked micelle as mold |
| 09/01/2004 | EP1452177A1 Pharmaceutical formulations comprising sodium laurylsulfate as bitterness masking agent |
| 09/01/2004 | EP1452174A1 METHOD OF STABILIZING REDUCED COENZYME Q sb 10 /sb |
| 09/01/2004 | EP1452173A1 UV-stable transdermal patch |
| 09/01/2004 | EP1452172A2 Multiple unit pharmaceutical preparation |
| 09/01/2004 | EP1452171A2 Pharmaceutical liquid suspensions |
| 09/01/2004 | EP1452170A1 Fluid-jet pens configured for modulated release of bioactive agents |
| 09/01/2004 | EP1452169A1 Aqueous base liquid pharmaceutical compositions in suspension form for the oral administration of ibuprofen |
| 09/01/2004 | EP1451571A2 Dosing and administration of therapeutic micro-organs in living subjects and devices and methods for same |
| 09/01/2004 | EP1451308A2 Therapeutic use of aziridino compounds |
| 09/01/2004 | EP1451294A2 Nutrient medium for maintaining neural cells in injured nervous system |
| 09/01/2004 | EP1451242A1 Water-in-silicone emulsions |
| 09/01/2004 | EP1451184A1 Dimeric compounds and their use as anti-viral agents |
| 09/01/2004 | EP1451183A1 Dimeric compounds and their use as anti-viral agents |
| 09/01/2004 | EP1451182A1 Dimeric compounds and their use as anti-viral agents |
| 09/01/2004 | EP1451144A1 Compositions for treating acne comprising phytandiol amine |
| 09/01/2004 | EP1451104A1 Calcium metasilicates and methods for making the same |
| 09/01/2004 | EP1450941A1 Perfuming or flavouring microcapsules comprising a fireproofing agent |
| 09/01/2004 | EP1450867A1 Sterilizing tunnel for pharmaceutical containers |
| 09/01/2004 | EP1450847A2 Apo2 ligand/trail formulations |
| 09/01/2004 | EP1450844A2 Polymeric thiol-linked prodrugs employing benzyl elimination systems |
| 09/01/2004 | EP1450842A2 Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and products thereof |
| 09/01/2004 | EP1450838A1 Method of treating hepatitis virus infection with a multiphasic interferon delivery profile |
| 09/01/2004 | EP1450836A2 Method for short-term and long-term drug dosimetry |
| 09/01/2004 | EP1450831A2 Methods of treatment in situ in the lungs of mammals |
| 09/01/2004 | EP1450829A1 Storage-stable fibrinogen solutions |
| 09/01/2004 | EP1450824A1 Pharmaceutical composition |
| 09/01/2004 | EP1450818A2 A method for treating inflammatory bowel disease |
| 09/01/2004 | EP1450813A1 Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of dysmenorrhea and menorrhagia |
| 09/01/2004 | EP1450807A1 Method of treating depression with delta receptor agonist compounds |
| 09/01/2004 | EP1450805A1 Method for the treatment of overactive bladder |
| 09/01/2004 | EP1450804A1 Pharmaceutical formulations comprising an immune response modifier |
| 09/01/2004 | EP1450803A1 New uses for anti-malarial therapeutic agents |
| 09/01/2004 | EP1450798A1 Use of an ascomycin for the treatment of blepharitis |
| 09/01/2004 | EP1450788A1 Use of coumarin or its hydroxy derivative for the treatment of medium or severe vascular and/or lymphatic edema |